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Abstract

Objective To comprehensively assess evidence on the
measurement properties of the minimal disease activity
(MDA) criteria, a composite measure of the state of disease
activity in psoriatic arthritis (PsA).
Methods A targeted literature review was conducted to
identify studies that informed the validity and/or ability
of the MDA to detect change among patients known to
have experienced a change in clinical status. The search
was conducted using MEDLINE and Embase databases
(published as of October 2017). Pertinent articles provided
by investigators and identified from select conference
proceedings were also evaluated.
Results A total of 20 publications met the inclusion
criteria. The MDA criteria were consistently associated
with other indicators of disease activity/severity. The
ability of the MDA criteria to detect change was supported
in randomised controlled trials (n=10), with a greater
percentage of patients randomised to active treatments
achieving MDA relative to patients in comparator arms.
Long-term observational studies (n=2) provided additional
support for the ability of the MDA to detect within-subject
change in the real-world settings.
Conclusion Evidence supports the MDA as a valid
measure of disease activity in PsA that can detect
between-group and within-subject change. The MDA
is a comprehensive measure and clinically meaningful
endpoint to assess the impact of interventions on PsA
disease activity.

Introduction
Psoriatic arthritis (PsA) is a chronic
immune-mediated inflammatory musculoskeletal disease.1 As an immune-mediated
disease with heterogeneous manifestations,
it typically presents with skin and musculoskeletal symptoms, including skin and nail
psoriasis, peripheral arthritis, enthesitis,
dactylitis and spondylitis.2 3 PsA may result in
permanent joint damage leading to reduced
health-related quality of life (HRQoL) and
physical function.2–4 Associated comorbidities include cardiovascular disease,1 3 5 metabolic syndrome,3 5 obesity,3 5 6 depression,1 3 5

Key messages
What is already known about this subject?
►► Psoriatic arthritis (PsA) is an immune-mediated dis-

ease with heterogeneous manifestations. Currently,
available measures do not capture all relevant aspects of the PsA disease activity, thus emphasising
the need for a disease assessment tool that is targeted and comprehensive, which can assess multiple domains of the disease.

What does this study add?
►► This is a targeted literature review of the available

evidence that supports utility, validity and relevance
of the minimal disease activity (MDA) as a measure
of disease activity in PsA.

How might this impact on clinical practice?
►► This targeted literature review provides supportive

evidence for MDA criteria as a targeted, practical
and easy to interpret measure that can be used in
both clinical practice and randomised controlled trials to assess disease activity in PsA.

anxiety,1 3 5 and may include conditions, such
as inflammatory bowel disease3 5 and uveitis.5 7
Prevalence among the general population has
been reported to range from 1 to 420 cases per
100 000 globally; and 250 cases per 100 000 in
the USA.8 Among patients with psoriasis, the
prevalence varies from 6% to 41% depending
on study methodology3 and the annual incidence has been reported to be approximately
3% in patients followed prospectively.9 Diagnosis and assessment of PsA is complex as a
result of heterogeneity in disease presentation and the presentation of symptoms that
evolve over the course of the disease.10 11
Patients can experience periods of disease
flares, minimal disease activity (MDA) and
remission.12
The ultimate treatment goal for PsA is clinical remission or inactive disease.13 14 Since,
for many patients, complete remission may
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Table 1 Relationship between MDA status and CRP

Author (year)

Study description

CRP score,
median (IQR); mean
(SD)

Sample size

MDA subgroup

Coates and Helliwell Post hoc analysis of two
RCTs to validate the MDA
(2010)22
criteria

157

MDA (n=63)

Median, 0.4 mg/dL
(0.4–0.6)

Non-MDA (n=94)

Median, 0.5 mg/dL
(0.4–1.3)

P value

0.019

Queiro et al (2017)25

277

MDA (n=133)

Mean, 2.8 mg/L (3.9)

Non-MDA (n=144)
P value

Mean, 4.7 mg/L (8.2)
<0.05

Cross-sectional
observational study

CRP, C reactive protein; MDA, minimal disease activity; Non-MDA, patients not achieving MDA; RCT, randomised controlled trial.

be difficult to attain, MDA, low or very low disease activity
(VLDA) have been proposed as alternative goals. Given
the multiple domains of PsA, a composite endpoint that
captures all relevant aspects of the disease is critical to
the overall interpretation of research study results and
patient management. The PsA core domain set recommended by the Group for Research and Assessment of
Psoriasis and Psoriatic Arthritis (GRAPPA)/Outcome
Measures in Rheumatology (OMERACT) for randomised
controlled trials (RCTs) and long-term observational
studies includes musculoskeletal disease activity, skin
disease activity, fatigue, pain, patient global assessment
(PtGA), physical function, HRQoL and systemic inflammation (defined by acute phase reactants) as key domains
that are important to both patients and physicians.15 The
most common PsA endpoint for Food and Drug Administration approval of treatments is the American College
of Rheumatology (ACR) response criteria,16 which were
developed as an endpoint for rheumatoid arthritis RCTs.
The ACR response criteria do not capture the distinct
features of PsA, such as enthesitis, dactylitis, axial disease
or skin manifestations, thus, additional instruments to
assess these manifestations are included in RCTs, such as
the Psoriasis Area Severity Index (PASI) and assessments
for the presence of dactylitis and enthesopathy.17–19
Several composite disease measures have been proposed,
including Disease Activity in Psoriatic Arthritis (DAPSA;
focuses solely on arthritis), Composite Psoriatic Disease
Activity Index (CPDAI), Psoriatic Arthritis Disease Activity
Score (PASDAS), Psoriatic Arthritis Response Criteria
(focuses solely on arthritis) and GRAPPA Composite
Exercise Index.20 These measures are all continuous and
remission is generally defined as a score below a cut-off
value.
Recognising the need for a tool to better capture
heterogeneous disease activity among PsA patients that
equates to a clinically meaningful indicator of disease
status, Coates et al developed a PsA-specific, composite
measure of disease state, the MDA criteria.21 22 The MDA
criteria were developed consistent with OMERACT
recommendations. In contrast to continuous measures,
the MDA serves as an indicator of the current state of

PsA disease.20 Patients achieve MDA if they meet five of
seven criteria: tender joint count ≤1; swollen joint count
≤1; PASI ≤1 or body surface area (BSA) ≤3; patient pain
Visual Analogue Scale (VAS) ≤15; PtGA ≤20; Health
Assessment Questionnaire (HAQ) ≤0.5 and tender
entheseal points≤1 (21). MDA response rates have been
assessed in longitudinal observational studies (LOSs) and
RCTs.20 Individual components of the MDA criteria are
well established. Of the seven individual components, five
components are included in the ACR response criteria
and the remaining two components (ie, PASI ≤1 or BSA
≤3 and tender entheseal points ≤1) have been used in
RCTs to assess the efficacy of PsA treatments. The MDA is
gaining acceptance as a meaningful composite index that
can be used to monitor disease activity across all PsA clinical pathologies23 and has been proposed as a comprehensive measure for treat-to-target (T2T) approach in
PsA.13 Recently, VLDA has become a clinically relevant
benchmark for disease remission and has been defined
as meeting seven of the seven MDA criteria.23
The objectives of this targeted literature review were
to comprehensively assess evidence regarding the performance characteristics of the MDA criteria and their utility
as a measure of disease activity in PsA. Specifically, this
review focused on summarising evidence of the validity
of the MDA criteria, and the ability of the MDA criteria
to detect between-groups and within-patient differences.
The focus of this review was on MDA but when available,
VLDA was reported.
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Methods
Search methodology
A targeted literature review was conducted to identify the
existing evidence for the measurement properties of the
MDA. Publications were identified using MEDLINE with
PubMed Interface and Embase databases and there were
no language or time frame restrictions for the literature
search. The search terms used from controlled vocabularies MeSH were: ‘minimal disease activity, minimal
disease activity index, minimal disease activity measure,
psoriatic arthritis, psoriatic arthropathy, surveys and

Psoriatic arthritis
Table 2 Relationship between MDA status and measures of structural damage

Author (year) Study description

Definition
joint damage
progression

Analysis
population/
subgroups

Time point Subgroup

Presence of hand
erosions

Cross-sectional studies
Queiro et al
(2017)25

Cross-sectional
observational study

Presence of
hand erosions
by radiographic
evidence

—

—

MDA (n=133)

30.8%

Non-MDA
(n=144)
P value

44.7%

Coates and
Helliwell
(2010)22

Prospective longitudinal
observational study to
establish the frequency
and predictors of MDA

If any joint changed MDA at consecutive visits* Mean follow- MDA (n=116)
from being non≥12 months (n=116)
up 34 months
damaged to
Non-MDA (n=228)
Non-MDA
damaged
(n=200)

Post hoc analysis of two
RCTs to validate the MDA
criteria

Increase in modified Phase II RCT (n=63)
SHS score of >0

Week 50

Week 100

Phase III RCT (n=157)

Geijer et al
(2015)27

Prospective longitudinal
observational study to
evaluate the course of
the disease and identify
predictors of progression

Kavanaugh et Post hoc analysis of
RCT, placebo to explore
al (2016)28
relationship of MDA to
radiographic progression

<0.05
Percentage of
patients with no
progression of joint
damage or mean (SD)
of joint damage score

Longitudinal studies
Coates et al
(2010)26

Measure

Wassenberg score

—

Week 54

256 week
follow-up

69
51

P value

<0.001†

MDA (n=26)

96

Non-MDA (n=37)

67

P value

0.012

MDA (n=12)

100

Non-MDA (n=25)

58

P value

0.03

MDA (n=63)

78

Non-MDA (n=94)

57

P value

0.009

MDA (males‡,
n=10)

3.4 (3.99)

Non-MDA (males, 10.94 (14.36)
n=19)
Increase in SHS
score >0

In MDA ≥3 consecutive
visits over the course
of the 256 week study
(n=116)

256 weeks

In MDA ≥4 consecutive
256 weeks
visits over the course of
the 256 week study (n=95)

P value

0.042

MDA (n=41)

35.3

Non-MDA (n=75)

NR

P value

0.054

MDA (n=34)

35.8

Non-MDA (n=61)

23.2

P value

0.056

*Patients evaluated every 6–12 months.
†P value represents comparison of mean change in joint damage over the study period in MDA versus non-MDA.
‡Mean scores not reported for females; however, it was noted that the statistical comparison of joint damage for MDA versus non-MDA was not significant.
MDA, minimal disease activity; Non-MDA, patients not achieving MDA; NR, not reported; RCT, randomised controlled trial; SHS, Sharp/van der Heijde Score.

questionnaires, questionnaires and rating scales, outcome
assessment, minimal important change,’ and combinations thereof. In addition, pertinent articles provided by
the investigators were evaluated for selection, including
abstracts from conference proceedings from the annual
ACR meetings and EULAR meetings. The same selection
criteria were applied to articles identified in literature
databases and to conference abstracts.
Publications were identified in two separate literature
searches. The first was conducted in February 2016; this
search was updated in October 2017.

Study selection and data extraction
After an initial screen of title and abstract, potentially
relevant full-text publications were retrieved for further
review. Articles were included if they provided evidence
regarding the development or measurement properties
of the MDA. Publications were excluded if they met any
of the following criteria: reported only the rationale for
developing the MDA; examined the relationship between
baseline variables associated with achievement of MDA
but did not inform measurement properties; clinical
effectiveness studies with no comparator group; and
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Table 3 Relationship between MDA status and PRO measures
Author (year)

Study description

Sample size

Time point

Criterion variable

MDA subgroup

Cross-sectional
observational study

277

—

PsAID total score*

MDA

3.3 (3.1)

Non-MDA

7.1 (5.2)

P value

<0.001

Cross-sectional studies
Queiro et al (2017)25

Mean (SD)

Longitudinal studies
Mease et al (2017a)31

Change from baseline
Post hoc analysis of
RCT to validate MDA
criteria and HRQoL
outcomes

135

Week 24

SF-36 PCS

SF-36 MCS

DLQI total

FACIT Fatigue

Coates et al (2016)30

Score

Post hoc analysis of
RCT to validate MDA
criteria and HRQoL
outcomes

397

Week 24

SF-36 PCS

SF-36 MCS

DLQI

FACIT fatigue

PsA QoL

Week 52

SF-36 PCS

SF-36 MCS

DLQI

FACIT fatigue

PsA QoL

MDA

13.3

Non-MDA

3.5

P value

<0.001

MDA

5.0

Non-MDA

0.3

P value

<0.01

MDA

−5.8

Non-MDA

−2.8

P value

0.01

MDA

8.6

Non-MDA

1.3

P value

0.001

MDA

9.0

Non-MDA

4.6

P value

<0.001

MDA

6.9

Non-MDA

4.1

P value

<0.01

MDA

−9.9

Non-MDA

−7.5

P value

<0.01

MDA

9.0

Non-MDA

4.9

P value

<0.001

MDA

−5.2

Non-MDA

−3.3

P value

<0.001

MDA

9.9

Non-MDA

4.6

P value

<0.001

MDA

6.8

Non-MDA

4.4

P value

<0.01

MDA

−10.7

Non-MDA

−8.5

P value

<0.01

MDA

9.5

Non-MDA

5.4

P value

<0.001

MDA

−5.7

Non-MDA

−3.4

P value

<0.001

*PsAID total score ranges from 0 (best health status) to 10 (worst health status).
DLQI, Dermatology Life Quality Index; FACIT, Functional Assessment of Chronic Illness Therapy; HRQoL, health-related quality of life;MCS, Mental Component Score; MDA, minimal
disease activity; Non-MDA, patients not achieving MDA;PCS, Physical Component Score; PROs, patient-reported outcomes; PsAID, Psoriatic Arthritis Impact of Disease; PsA QoL,
psoriatic arthritis quality of life; RCT, randomised controlled trial; SF-36, Short Form 36 Health Survey.
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Table 4 Kappa’s agreement between MDA and alternate disease activity criteria
Author (year)

Sample
size

Time point

Criterion

κ

Prospective longitudinal observational study of
GRACE dataset collected from 32 countries to
explore the relationship between MDA and low
disease activity cutoffs

503

Week 24

PASDAS

0.73

CPDAI-4

0.75

CPDAI-3

0.75

Prospective longitudinal observational study

223

DAS28 (<2.6)

0.65

DAS28 deep remission (1.98)

0.60

DAPSA remission (≤4)

0.65

4 months

PtGA

0.73

8 months

PtGA

0.72

12 months

PtGA

0.73

Week 24

MDA-joints*

0.86

MDA-phys†

0.48

Study description

Measures of disease activity
Coates and Helliwell
(2016)32

Rahman et al (2017)33

Lubrano et al (2015)34

Prospective longitudinal observational study to
compare PtGA with MDA and other outcome
measures.

124

12 months

Categorical measures
Coates and Helliwell
(2016)32

Described above

503

*BSA, and not the PASI, was the cut-off used for the skin domain.
†MDA as judged by the treating physician=do you think this patient is in an MDA state? (yes/no).
BSA, body surface area; CPDAI, Composite Psoriatic Disease Activity Index; DAPSA, Disease Activity in Psoriatic Arthritis; DAS28, Disease Activity Score using 28 joints; GRACE,
Group for Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) Composite Disease Exercise; MDA, minimal disease activity; PASDAS, Psoriatic Arthritis Disease Activity Score;
PASI, Psoriasis Area and Severity Index; PtGA, patient global assessment.

conference abstracts except those reporting results of
phase III RCTs.
All studies were reviewed by an independent reviewer
and the following data were extracted: author and year of
publication; study characteristics, including study design
and type (including but not limited to RCTs and post
hoc analysis of RCTs; LOS and post hoc analyses of LOS;
study years; sample size; study population characteristics; experimental treatment and findings related to the
measurement properties of the MDA.
To evaluate the validity of the MDA, reported clinical endpoints were assessed and descriptive data and
statistical comparisons were extracted for patients in
MDA versus non-MDA for the following variables, where
available:
1. C reactive protein (CRP)—patients in MDA were expected to have lower CRP levels, indicative of overall
lower levels of inflammation.
2. Structural damage—patients in MDA were expected
to have less evidence of joint damage by radiographs
and/or clinical report.
3. Patient-reported outcomes (PROs)—patients in MDA
were expected to report better HRQoL, physical and
mental function, and lower levels of fatigue relative to
patients not in MDA.
To further evaluate the validity of the MDA, Kappa’s
agreement statistics were summarised between MDA and
alternate measures of disease activity, where available.
The kappa values associated with the level of agreement
are as follows: none (κ=0–0.2); minimal (κ=0.21–0.39);
weak (κ=0.40–0.59); moderate (κ=0.60–0.79); strong
(κ=0.80–0.90) and almost perfect (κ>0.90).24
To determine the ability of the MDA to detect changes
in clinical studies, descriptive data and statistical comparisons were extracted for treatment and comparator groups
in RCTs and LOS. Study drugs with known efficacy were

Validity
MDA status and CRP
Two studies assessed the relationship between MDA and
CRP, a marker of systemic inflammation (table 1).
Coates and Helliwell evaluated the ability of the MDA
to differentiate among patients based on CRP and found
an association between CRP levels and achievement of
MDA.22 In this analysis, CRP levels were significantly
lower in patients who achieved MDA than in those who
did not (p=0.019). Results of a cross-sectional observational study among Spanish PsA patients published by
Queiro et al were consistent with the above findings.25
Queiro et al reported that CRP scores were significantly
lower in patients in MDA than in those who were not
(p<0.05).
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assessed for the percentage of patients taking the active
treatment relative to the comparator arm in achieving
MDA; a greater percentage receiving active treatment
were expected to achieve MDA compared with those
receiving placebo.
Results
Search results and study characteristics
The combined literature reviews identified 20 relevant
publications that provided information on the measurement properties of the MDA and these were selected
for data extraction. One publication was a conference
abstract presenting results of a phase III trial and the
remainder of the publications were journal articles.
Of these 20 publications, nine articles reported results
from observational studies and the remaining reported
results from RCTs. All publications that met eligibility
criteria are summarised in online supplementary table
S1.

RMD Open
Table 5 Ability to detect change in RCTs
Sample size
Author (year)

Study description

Total

Coates and Helliwell Post hoc analysis of two RCTs Phase 2=63
to validate the MDA criteria
(2010)22

Phase 3=157

Coates et al (2016)30 Post hoc analysis of phase
III RCT

397

PsA only
63

157

397

Time point

Primary comparison

Percentage
of patients
achieving MDA

Week 16

Infliximab

48

Placebo

3

P value

<0.0001

Infliximab

52

Placebo*

21

P value

<0.001

Secukinumab 150 mg

23

Secukinumab 300 mg

28

Placebo

10

Secukinumab 150 mg

33

Secukinumab 300 mg

35

Tofacitinib 5 mg

22.9

Tofacitinib 10 mg

21.2

Placebo

14.5

P value

NR

Tofacitinib 5 mg

23.7

Tofacitinib 10 mg

23.5

Placebo/tofacitinib 5 mg

18.2

Placebo/tofacitinib 10 mg

29.2

P value

NR

Golimumab

23.5

Placebo

1

P value

<0.0001

Golimumab

28.1

Placebo

7.7

P value

<0.0001

Golimumab

42.4

Placebo

30.2

P value

<0.0001

Golimumab

24.9

Placebo

12.3

P value

0.007

Golimumab

16.6

Placebo

2.8

P value

0.000

Golimumab

11.4

Placebo

0

P value

0.000

Adalimumab

36.4

Placebo

5.8

P value

<0.001

Week 24

Week 16

Week 52

Gladman et al
(2017)41

Phase III RCT, placebo

394

394

Week 12

Week 28

Kavanaugh et al
(2016)28

Post hoc analysis of
RCT, placebo to explore
relationship of MDA to
radiographic progression

395

395

Week 14

Week 24

Week 52

≥5 consecutive time
points

≥6 consecutive time
points

≥7 consecutive time
points

Mease et al (2017)31

Phase III RCT
313
(week 24—active treatment
end of study; weeks 48–144—
open-label extension)

136

Week 24

Week 48
Adalimumab
(open-label extension)
Adalimumab naïve

43.1

Week 96
Adalimumab
(open-label extension)
Adalimumab naïve

37.9

Week 144
Adalimumab
(open-label extension)
Adalimumab naïve

34.5

32.2

27.1
22.0

Continued

6
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Table 5 Continued
Sample size
Author (year)

Study description
42

Mease et al (2014)

Mease et al (2015)43

Mease et al (2017)19

Total

Post hoc analysis of RCT data 409
to explore relationship with
MDA

Post hoc analysis of RCT data 409
to explore relationship with
MDA

Post hoc analysis of RCT,
placebo to investigate
achievement of MDA

424

PsA only

Time point

Primary comparison

409

Week 24

Certolizumab pegol
(200 mg and 400 mg)

33.3; 34.1

Placebo

5.9

P value

<0.001

409

424

Week 48 (imputation)

Certolizumab pegol
38.8
(combined patients
randomised to active treatment
at baseline)

Week 96 (imputation)

Certolizumab pegol
41.0
(combined patients
randomised to active treatment
at baseline)

Week 24

Abatacept

11.7

Placebo

8.1

P value

0.205

Week 52
Abatacept
(open-label extension)
Placebo/abatacept
44

Mease et al (2017)

Phase III RCT to investigate
achievement of MDA

422

Week 12

422

Week 52

Nash et al (2017)45

Post hoc analysis of RCT,
placebo to investigate
achievement of MDA

363

Percentage
of patients
achieving MDA

363

Week 24

17.4
18.5

P value

NR

Tofacitinib
(5 mg and 10 mg)

26.0; 26.0

Adalimumab

25.0

Placebo (pooled)

7.0

P value

NR

Tofacitinib
(5 mg and 10 mg)

37.0; 43.0

Adalimumab

40.0

Placebo/tofacitinib
(5 mg and 10 mg)

31.0; 34.0

P value

NR

Ixekizumab
(2 weeks; 4 weeks)

24.0; 28.0

Placebo

3

P value

<0.0001

*Forty-seven patients in the placebo group entered the early escape arm at week 16 and received infliximab.
MDA, minimal disease activity; NR, not reported; PsA, psoriatic arthritis; RCT, randomised controlled trial.

MDA status and measures of structural damage
Queiro et al reported the relationship between MDA and
presence of radiographic erosions in the hands and feet
in a cross-sectional study (table 2).25
Patients in MDA were less likely to have evidence
of hand erosions compared with those who were not
(p<0.05); however, there were no significant differences
among patients when evaluating presence of erosions in
the feet.
Four longitudinal studies reported the progression of
structural damage over time in patients achieving MDA
and in those who did not (table 2).22 26–28 Across these
studies, patients in MDA had lower rates of structural
damage progression; these differences were statistically
significant in three of four studies. In a post hoc analysis of phase II and phase III RCTs, Coates and Helliwell reported that patients in MDA were less likely to
exhibit structural damage progression.22 In the phase
II RCT, patients achieving MDA were significantly less

likely to have increases >0 in the modified Sharp/van
der Heijde Scores (SHS) at week 50 (p=0.012) and
week 100 (p=0.03) compared with patients not in MDA.
In the phase III trial, patients in MDA at week 54 were
also less likely to have evidence of structural damage
progression (p=0.009). Kavanaugh et al conducted a
post hoc analysis of a phase III RCT that reported the
relationship between achievement of MDA over consecutive study visits (≥3 visits and ≥4 visits) and increases in
SHS >0 over the 256-week treatment period.28 Results
for both subgroups (≥3 and ≥4) were in the anticipated
direction; however, they were not statistically significant (p=0.054 and p=0.056, respectively). Coates et
al assessed the rate of structural damage progression
over a 5-year prospective LOS among patients in MDA
and those who were not.26 The average follow-up was
34 months and patients in MDA were significantly less
likely to have structural damage progression (p<0.001).
The rate of structural damage progression by the
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Table 6 Ability to detect change in prospective LOS

Author (year)

Study description

Rahman et al
(2017)33

Biological treatment registry to
examine MDA rate over time

Perrotta et al
(2016)36

Prospective longitudinal study
to examine MDA status with the
indices of disease activity and to
identify predictors for MDA

Sample
size
233

75

Treatment

Time point

Percentage
of patients
achieving MDA

Infliximab, golimumab, Baseline
ustekinumab
Week 26

11.7

Week 52

44.8*

P value

<0.001

Adalimumab,
etanercept,
golimumab

43.5*

Baseline

0

4 months

22.6

8 months
12 months

56.0
61.3†

*P<0.001.
†Article reports the percentage of patients achieving MDA status at 12 months was significantly different from baseline but does not report p
value.
LOS, longitudinal observational studies; MDA, minimal disease activity.

Wassenberg score over a 256-week follow-up period in
a prospective LOS has been reported by Geijer et al for
a cohort of PsA patients in Sweden and was found to be
significantly lower among patients in MDA (p=0.042).27
MDA status and PROs
Three studies examined the relationship between MDA
status and PROs and are summarised in table 3.
The relationship between MDA status and physical and
psychological function measured by the PsA Impact of
Disease Questionnaire (PsAID) was evaluated by Queiro
and colleagues in an observational, cross-sectional
study.25 The PsAID measures the physical and psychological impact of disease on patients’ lives.29 Results indicated that patients in MDA reported significantly lower
impacts of disease than patients who were not in MDA
across all domains and total PsAID scores (p<0.001).25
Eighty-eight (66.7%) MDA patients reported a PsAID
score <4 compared with 34 (37.4%) non-MDA patients
(p<0.0001).
Two studies reported the relationship between changes
over time in PROs and MDA. In both, patients in MDA
reported significantly more improvements across all
PROs assessing HRQOL and fatigue: Short Form 36
Health Survey, Dermatology Life Quality Index (DLQI),
Functional Assessment of Chronic Illness Therapy-Fatigue, and PsA quality of life.30 31 Additional data from
these studies are summarised in table 3.
Agreement between MDA and alternative measures of
disease activity
Several publications evaluated the relationship between
MDA and other overall disease activity indicators (such
as the PASDAS, CPDAI, Disease Activity Score (DAS),
DAPSA and PtGA) by calculating Kappa’s (κ) coefficients
(table 4).
Coates and Helliwell reported moderate agreement
(κ=0.73–0.75) with three alternative definitions of
8

treatment responses: PASDAS, CPDAI-4 and CPDAI-3.32
Agreement was also strong for MDA joints (κ=0.86) but
weak for MDA-phys (κ=0.48). The relationship between
MDA and disease activity reported by the patient
(measured as a patient-reported overall indicator of
disease activity) was also evaluated. The κ coefficient
between MDA and patients’ rating of whether they were
in a minimal disease state was 0.30.
Rahman et al reported a moderate κ agreement between
achievement of MDA and three additional disease activity
measures, including DAS using 28 joints (DAS28, <2.6),
DAS28 deep remission (DAS28 <1.98) and DAPSA remission (≤4).33 Lubrano et al reported moderate agreement
between MDA and a single item of the MDA, PtGA
(κ=0.72–0.73).34 As part of the same LOS, Lubrano et al
then evaluated the sensitivity and specificity in differentiating patients rated by their physician as being in MDA
(<10 mm on a 100 mm VAS) versus a higher disease state
(≥10); sensitivity was 0.90 (0.74–0.98) and specificity 0.69
(0.57–0.79).35
Ability to detect change
Ten RCTs that provide evidence on the between-patient
treatment effects of the MDA were identified (table 5)
and indicated that those who received treatment with
a targeted immunomodulator were significantly more
likely to achieve MDA than those who received placebo.
Two prospective LOS provide evidence on the within-patient treatment effects (table 6). In these studies,
over 1 year of treatment with a disease-modifying antirheumatic drug resulted in an increasing proportion of
patients achieving MDA.33 36
Very low disease activity
One study reported both MDA and VLDA from a post hoc
analysis of a 24-week RCT that compared adalimumab to
placebo. Mease et al reported that of 66 patients receiving
adalimumab, 24 (36.4%) achieved MDA and 10 (15.4%)
Coates LC, et al. RMD Open 2019;5:e001002. doi:10.1136/rmdopen-2019-001002
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VLDA. In contrast, of 69 patients in the placebo group,
only four (5.7%) and zero (0%), respectively, achieved
MDA and VLDA.31
Discussion
This targeted literature review assessed the current
evidence of the performance characteristics of the MDA
criteria and their utility as a measure of disease activity in
PsA. The validity and relevance of the MDA as a measure
of disease activity was strongly supported based on the
strength and consistent association between MDA status
and each of these domains.
Across studies, MDA responses were in the anticipated
direction of other disease indicators, such as CRP, structural damage progression, patient-reported HRQoL, pain
and fatigue and global assessments of disease activity. The
consistency reported in the literature provides strong
evidence that MDA is a valid indicator of disease activity
in PsA.
MDA is frequently reported in RCTs that examine the
efficacy of treatments for PsA. Across all RCTs included
in this literature review, a greater proportion of patients
assigned active treatment achieved MDA versus placebo/
control groups. A growing body of evidence also supports
the ability of the MDA criteria to detect within-patient
changes over time, providing further support for its use
in LOS and RCTs.
Recent T2T recommendations have highlighted the
aspiration for remission or VLDA, but for many patients,
low disease activity or MDA may be an appropriate
treatment target.13 The MDA criteria have been recommended by both the T2T international task force13 and
the GRAPPA/OMERACT group to assess treatment
target goals.37 While MDA does not measure disease
activity, it is a feasible target of treatment assessing
multiple domains of the disease. The MDA criteria can
be used in all patients with PsA regardless of their disease
pattern, whereas other measures do not reflect disease
activity across all subgroups of PsA. It gives a target that
is appropriate for both polyarticular and oligoarticular
patients. In some other measures (eg, ACR response
and DAPSA) of disease activity the focus is primarily on
articular inflammation,13 which may not reflect the full
range of disease activity in some PsA patients. PASDAS
is another disease activity measure that covers multiple
domains, but it does not include skin and is complex to
use in clinical practice at present.
Measures like MDA that generally focuses on multiple
domains of the disease can evade inclusion of patients
having an active domain, which may otherwise be categorised as cohort with remission or low disease activity.
van Mens et al reported that prevalence of skin disease
was higher in patients with PsA who had DAPSA remission compared with other measures. Given that DAPSA
is an unidimensional measure, it particularly focuses
only on peripheral joint disease. Hence, it does not
address important manifestations of PsA, where MDA, a
Coates LC, et al. RMD Open 2019;5:e001002. doi:10.1136/rmdopen-2019-001002

multidimensional measure, addresses all of them.38 In a
recently published study, Coates et al concluded that in
comparison with DAPSA, definitions of VLDA and MDA
are more stringent in evaluating PsA.39
The MDA criteria offer a targeted and easy to interpret disease assessment, and have been incorporated into
both clinical practice and trial settings.38 MDA is based on
commonly performed clinical examinations, with some
additional, easy to administer PROs (ie, PtGA, pain VAS
and HAQ) and skin evaluations (ie, PASI or BSA), and
determining MDA requires minimal training and time
for the required assessments. PRO measures are increasingly being incorporated into clinical practice settings,
which will further enable assessment of MDA.40
There are several limitations to this targeted literature
review that warrant consideration when interpreting the
results presented in this manuscript. This review sought
to qualitatively characterise information on the measurement properties of the MDA. Although a thorough
search strategy was employed to capture all pertinent
publications, the potential exists that not all relevant
publications were identified. Further investigation into
this is needed to evaluate stability of the score among
patients with stable disease activity. Furthermore, each of
the studies included in this review used different methodological approaches to study design (cross-sectional
vs longitudinal), population analysed, study duration
and endpoints evaluated, thereby limiting the ability to
collectively summarise findings.
This literature review provides a detailed evaluation
of the measurement properties of the MDA and shows
strong evidence for the validity of the MDA as a measure
of PsA disease activity and its sensitivity to detect changes
with treatment. Substantial data support its use as a practical, comprehensive and clinically meaningful endpoint
for clinicians to assess the impact of specific treatment
interventions on PsA disease activity.
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